As of October 8, 2026, UnitedHealth Group’s reported outlook is stronger than it was after the first quarter. Following second-quarter results, management raised its full-year 2026 adjusted earnings-per-share outlook to $19.50–$20.00, up from the “greater than $18.25” it gave with first-quarter results. That is evidence that expected earnings improved. It is not a forecast for the share price, and the company’s reports say nothing about where the stock trades today. The next test is the third-quarter report, due October 13, 2026.
What the first quarter actually showed
The “slump” in the headline describes how the shares traded. The company’s own first-quarter figures do not show a revenue decline: revenue was $111.7 billion, up 2% year over year. The figures below are company-reported, not independent assessments.
![[Brandon Turner]-The Book on Rental Property Investing- How to Create Wealth and Passive Income Through Intelligent Buy & Hold Real Estate Investing! (SoftCover)](https://m.media-amazon.com/images/I/51mMR6cQZCL._SL160_.jpg)
| Measure (company-reported) | Q1 2026 | Q2 2026 |
|---|---|---|
| Revenue | $111.7 billion, up 2% year over year | $112.0 billion |
| Reported EPS | $6.90 | $6.04 |
| Adjusted EPS | $7.23 | $6.38 |
| Full-year 2026 adjusted EPS outlook after the quarter | Greater than $18.25 | $19.50–$20.00 |
The gap between reported and adjusted EPS was about $0.33 in Q1 and $0.34 in Q2. This article does not itemize the adjustments. If you want the unadjusted picture, start with reported EPS.
What changed after Q2
On July 16, after second-quarter results, management raised its full-year 2026 adjusted EPS range to $19.50–$20.00. The midpoint of $19.75 is $1.50, or about 8%, above the earlier “greater than $18.25” figure. Because that earlier number was a floor rather than a point estimate, treat the 8% as approximate. Guidance is management’s forecast, not a commitment.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11#1 Best Overall
The second-quarter operating picture is more mixed than the headline raise suggests, so compare it directly with the prior-year quarter:
| Q2 2026 measure | Q2 2026 | Comparison |
|---|---|---|
| Medical care ratio | 86.7% | 89.4% in Q2 2025 |
| Operating earnings | $8.0 billion | $5.2 billion in Q2 2025 |
| Net favorable prior-period development | $860 million | Not stated in the Q2 2026 results |
| Net margin | 4.9% | Not stated in the Q2 2026 results |
What the guidance implies for the second half
Simple arithmetic on reported adjusted EPS shows how much of the year now sits in the back half. Q1 ($7.23) and Q2 ($6.38) total $13.61. Against the new range, that leaves $5.89–$6.39 for Q3 and Q4 combined, an average of roughly $2.95–$3.20 per quarter. Before Q2, the first-quarter outlook implied more than $11.02 across Q2 through Q4.
Rank #2
- WHAT'S INCLUDED: 110 durable (3"x5") flashcards covering all the essential aspects of fundamental analysis. Learn to analyze financial statements, key ratios, valuation metrics, and stock evaluation techniques like a pro. Plus, get 1 month of exclusive access to an online training and research platform focused on fundamental analysis for evaluating companies. Simply scan the QR code on your thank-you card to access your digital content.
- MASTER DEFINITIVE INVESTMENT PRINCIPLES, SUITABLE FOR INVESTORS AND TRADERS, Providing a Clear Roadmap for Understanding Financial Metrics and Analyzing Stocks.
- DISCOVER THE POWER OF QUICK STUDY CARDS: An Effective Alternative to Lengthy Books. They Deliver Precise, Focused Information on Financial Metrics and Stock Analysis, Making Learning Fun and Efficient for Investors and Traders.
- INSTANTLY RECOGNIZE STOCK VALUATION TRENDS AND IDENTIFY HIDDEN OPPORTUNITIES with Strategies Most Investors and Traders Overlook.
- DON'T WASTE TIME ON LOW-PROBABILITY INVESTING STRATEGIES. Focus on Learning High Probability, High Payout Strategies for Optimal Investing Success.
Two cautions apply. Per-share totals are approximate because share counts change from quarter to quarter. The company materials cited here also do not explain why earnings are weighted toward the first half. Treat the implied second-half figure as arithmetic on guidance, not a forecast. The third-quarter call is the place to ask whether the phasing is seasonal or reflects pressure.
Reading the medical care ratio
The medical care ratio, the share of revenue paid out as medical costs, is the figure most likely to drive reaction to the third-quarter report. The 86.7% ratio in Q2 is 2.7 points better than the 89.4% a year earlier, but one adjustment matters.
Rank #3
- Stock Market Investing design. Are you looking for a suitable gift? Then you should buy this outstanding design. People will love this cool motif. Great gift for your mother, dad, grandfather, grandmother, uncle, aunt, sister or brother.
- An ideal gift idea for lovers and fans whether for Christmas or birthday. A great surprise for any special occasion such as Father's Day, Mother's Day and any other anniversary. Dad, mum, grandpa or grandma will love it.
- Lightweight, Classic fit, Double-needle sleeve and bottom hem
The company reported $860 million of net favorable prior-period development in Q2. Favorable development means earlier estimates of medical costs turned out to be too high, which lowers the ratio in the quarter it is recorded. The company said most of the amount related to 2026 dates of service. That wording is worth reading in the full release, because “prior-period” usually refers to earlier years rather than the current one. Either way, a reserve adjustment is not an operating gain that repeats on its own.
Excluding that $860 million, the ratio would have been roughly 87.5%, about 0.8 points higher. This is an approximation that assumes the whole amount sits in medical costs and revenue is unchanged. On that basis, the year-over-year improvement is about 1.9 points rather than 2.7.
The full-year outlook is 88.1%, plus or minus 25 basis points, or 87.85% to 88.35%. Adjusted for the reserve benefit, the Q2 figure sits below that band. Quarterly ratios vary, and the figures cited here do not include a first-quarter ratio, so one quarter cannot establish a trend.
Membership, cash and the balance sheet
- Medicare Advantage membership: down 965,000 since year-end 2025, as stated in the Q2 release. Fewer members can support margins only if pricing and cost control offset the lost enrollment. The third-quarter membership figure will show whether they do.
- Operating cash flow: $11.1 billion in Q2, against a full-year cash-flow outlook of about $24 billion.
- Debt-to-capital: 41.2% at June 30, 2026.
- Share repurchases: the company plans at least $5 billion. This article does not confirm the period that figure covers.
Risks the company lists
The Q2 filing identifies the following risks, which bear directly on whether the improved guidance holds:
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errors- Estimating medical costs and setting prices
- Changes in Medicare policy and other regulation
- Department of Justice legal actions concerning Medicare participation
- Competition
- Cyber incidents
- Litigation
- Execution on the company’s plans
What to check on October 13
UnitedHealth scheduled its third-quarter results for Tuesday, October 13, 2026, before market open, with an 8:00 a.m. ET conference call. Use the table below to check the release against the reference points in this article.
| Signal | Reference point | Consistent with the improved outlook | Would weaken the case |
|---|---|---|---|
| Adjusted EPS outlook | $19.50–$20.00 | Range held or raised | Range lowered |
| Full-year medical care ratio | 88.1% plus or minus 25 basis points (87.85% to 88.35%) | Ratio stays in that band | Ratio runs above the band without another favorable reserve adjustment |
| Reserve development | $860 million favorable in Q2 | Development is a smaller share of earnings | Guidance depends on further large favorable adjustments |
| Medicare Advantage membership | Down 965,000 since year-end 2025 | Membership losses slow while margins hold | Further losses without offsetting margin gains |
| Cash flow and buybacks | About $24 billion full-year cash-flow outlook; at least $5 billion planned repurchases | Cash flow tracks the outlook and buybacks proceed | Cash flow falls short of the outlook or buybacks are reduced |
| Debt-to-capital | 41.2% at June 30, 2026 | Stays at or below that level | Rises above 41.2% |
What this article does not establish
This article does not give a current share price, analyst consensus, valuation or price target, and the company materials cited here do not include them. The company materials also do not document the size or cause of the share-price decline, or how the shares reacted to either guidance raise. Check a live quote and current analyst estimates before drawing a conclusion about the stock’s direction, and read the third-quarter release itself rather than summaries of it.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
